Top prize in the international iGEM Synthetic Biology competition 2019
Posted: 21st January 2020
Categories: Company news
We are happy to announce that we contributed to iGem Thessaloniki team’s won of the top prize in the international iGEM Synthetic Biology competition 2019, organized by MIT University in Boston. The project is called “POSEIDON” and it is a toolkit for the examination of DNA-Protein interactions. IGem team of Thessaloniki deploys the first DNA […]
Liquid biopsy option for advanced lung cancer patients
Posted: 6th January 2020
Categories: Company news
Liquid biopsy tests could be an option for patients with a form of lung cancer, according to the early results of research presented at a major cancer conference. A growing number of patients with advanced lung cancer could soon be offered a blood test to help to decide the best treatment for them instead of […]
In as little as two weeks, patients and clinicians can gain access to a next-generation genetic test provided by RGCC that can analyse the sequence of both DNA and RNA. The RGCC CAMBISeq (Cancer Analysis, Mutational Burden and Instability Sequencing) test sequences DNA and RNA – the nucleic acids that carry genomic sequence information and […]
Earlier this month Dr Ioannis Papasotiriou attended the IX Hyperthermie Kongress Berlin. The aim of the event is to share evidence and experience from daily practice on the treatment of chronic and oncological disease. Dr Papasotiriou was among a number of international speakers at the event and gave a speech about role of heat shock […]
Taking place very September, Thessaloniki International Fair is a leading B2B, B2C and B2G event. RGCC attended this year’s event, which ran from 7 to 15 September and celebrated innovation and international culture. Take a look at our film of the event.
Yes. Onconomics and Onconomics Plus tests can be used for Ras-Raf-MEK-Erk, dabrafenib, vemurafenib, c-Jun, C-Fos, trametinib and sorafenib.
Can the Oncotrace test differentiate between benign and malignant tumour cells?
Yes. The Oncotrace test provides information about the presence of circulating tumour cells, their concentration and immunophenotype, which may help identify their origin. It is used to provide guidance about a patient’s prognosis, and to help identify the primary tumour when this is unknown.
I have a patient whose specific tumour appears to have resisting populations because of the overexpression of the MDR1 gene. This can be reversed by the use of inhibitors of ABG2 pumps. What do I do?
In this case, a patient could proceed with ketoconazole as a first-line treatment, and verapanib as a second-line treatment. Verapanib can contribute to a fall in blood pressure.
Didn't find an answer to your question? Contact us directly.